Arcturus Therapeutics ARCT and partner CSL Seqirus, a renowned vaccine company, together reported encouraging results from a ...

CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger ...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus ...

Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...

AbbVie's (NYSE:ABBV) autoimmune disease biologic Humira (adalimumab) and Pfizer (NYSE:PFE)/BioNTech's (BNTX) COVID-19 shot ...

It’s been over four years since the beginning of the COVID-19 pandemic. And since then, the virus has changed substantially.

According to The People’s Vaccine Alliance, Comirnaty costs an estimated $1.18 per dose to produce. For over two years now, the US government has been running its public vaccination campaign ...

BioNTech is the Marketing Authorization Holder for COMIRNATY ® and its adapted vaccines (COMIRNATY ® (COVID-19 Vaccine, mRNA); COMIRNATY ® Original/Omicron BA.1; COMIRNATY ® Original/Omicron BA.

Omicron KP.2 variant adapted vaccine COMIRNATY is now authorized in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming weeks. The updated ...

2-adapted monovalent Covid-19 vaccine (Comirnaty KP.2) for active immunization to prevent Covid-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The European Commission will review ...